Mechanisms of pharmaceutical aerosol deposition in the respiratory tract

AAPS PharmSciTech

Volumn 15, Issue 3, 2014, Pages 630-640

  Cheng, Yung Sung ^a  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

aerosol deposition; drug delivery; inhalation; lung

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; NOSE SPRAY; AEROSOL; DRUG;

AEROSOL; COMPUTATIONAL FLUID DYNAMICS; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; HUMAN; INHALATION; INHALER; MEDICAL NEBULIZER; METERED DOSE INHALER; OROPHARYNX; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; SIMULATION; ANATOMY AND HISTOLOGY; ANIMAL; AUDIOVISUAL EQUIPMENT; BIOLOGICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; DEVICES; DOSE CALCULATION; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; NEBULIZER; PHARMACEUTICS; PROCEDURES;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; DRUG DOSAGE CALCULATIONS; EQUIPMENT DESIGN; HUMANS; MODELS, ANATOMIC; MODELS, BIOLOGICAL; NEBULIZERS AND VAPORIZERS; PHARMACEUTICAL PREPARATIONS; RESPIRATORY SYSTEM; TECHNOLOGY, PHARMACEUTICAL;

EID: 84901986886     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0092-0     Document Type: Review

References (67)

1. Newman SP. Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs. Br J Clin Pharm. 2000;49:529-37. (Pubitemid 30326552)
2. Derom E, Pauwels R. Relationship between airway deposition and effects for inhaled bronchodilators. In: Dalby R, Byron PR, Farr SJ, editors. Respiratory drug delivery VI. Buffalo Grove: Interpharm Press; 1998. p. 35-44.
3. Cheng YS. Modeling aerosol drug delivery. In: Gradon L, Marijnissen J, editors. Optimization of aerosol drug delivery. Dordrecht: Kluwer; 2003. p. 165-88.
4. Newman S, Bennett WD, Biddiscombe M, Devadason SG, Dolovich M, Fleming J, et al. Standardization of techniques for using planar (2D) imaging for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulmon Drug Deliv. 2012;25:S10-28.
5. Fleming J, Bailey DL, Chan HK, Conway J, Kuehl PJ, Laube BL, et al. Standardization of techniques for using single-photon emission computed tomography (SPECT) for aerosol deposition assessment of orally inhaled products. J Aerosol Med Pulmon Drug Deliv. 2012;25:S29-51.
6. ICRP. Human respiratory tract model for radiological protection. London: Pergamon; 1994. Publication 66, Annals of ICRP.
7. NCRP. Deposition, retention, and dosimetry of inhaled radioactive substances. Bethesda: National Council on Radiation Protection and Measurements; 1997. NCRP Report No. 125.
8. Anjilvel S, Asgharian B. A multiple-path model of particle deposition in the rat lung. Fund Appl Toxicol. 1995;28:41-50.
9. Ali M. Pulmonary drug delivery. In: Kulkarni V, editor. Handbook of non-invasive drug delivery systems. New York: Elsevier; 2010. p. 209-46.
10. Martonen TB. Mathematical model for the selective deposition of inhaled pharmaceuticals. J Pharm Sci. 1993;82:1191-9. (Pubitemid 23354135)
11. Pritchard JN, Layzell GR, Miller JF. Correlation of cascade impactor data with measurements of lung deposition for pharmaceutical aerosols. In: Drug delivery to the lungs VII. London: The Aerosol Society; 1996. p. 101-4.
12. Price A. Validation of aerosol deposition models for pharmaceutical purposes: the way forward. In: Dalby R, Byron PR, Farr SJ, Peart J, editors. Respiratory drug delivery VII. Buffalo Grove: Interpharm Press; 2000. p. 197-208.
13. Clark AR, Newman SP, Dasovich N. Mouth and oropharyngeal deposition of pharmaceutical aerosols. J Aerosol Med. 1998;11:S116-21. (Pubitemid 28286043)
14. DeHaan WH, Finlay WH. In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices. J Aerosol Med. 2001;14:361-7. (Pubitemid 32802039)
15. DeHaan WH, Finlay WH. Predicting extrathoracic deposition from dry powder inhalers. J Aerosol Sci. 2004;35:309-31. (Pubitemid 38294375)
16. Kleinstreuer C, Shi HW, Zhang Z. Computational analyses of a pressurized metered dose inhaler and a new drug-aerosol targeting methodology. J Aerosol Med. 2007;20:294-304.
17. Stahlhofen W, Gebhart J, Heyder J. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J. 1980;41:385-98.
18. Emmett PC, Aitken RJ, Hannan WJ. Measurements of the total and regional deposition of inhaled particles in the human respiratory tract. J Aerosol Sci. 1982;13:549-60. (Pubitemid 13509578)
19. Heyder J, Gebhart J, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range of 0.005-15 um. J Aerosol Sci. 1986;17:811-25. (Pubitemid 17492310)
20. Cheng YS, Zhou Y, Chen BT. Particle deposition in a cast of human oral airways. Aerosol Sci Technol. 1999;31:286-300. (Pubitemid 32001437)
21. Smith SM, Cheng YS, Yeh HC. Deposition of ultrafine particles in human tracheobronchial airways of adults and children. Aerosol Sci Technol. 2001;35:697-709. (Pubitemid 32823708)
22. Zhou Y, Cheng YS. Particle deposition in a cast of human tracheobronchial airways. Aerosol Sci Technol. 2005;39:492-500. (Pubitemid 40993227)
23. Asgharian B, Price OT. Deposition of ultrafine (nano) particles in the human lung. Inhal Toxicol. 2007;19:1045-54. (Pubitemid 350034850)
24. Phalen RF, Hinds WC, John W, Lioy PJ, Lippmann M, McCawley MA, et al. Rationale and recommendations for particle size-selective sampling in the workplace. Appl Ind Hyg. 1986;1:3-12.
25. Soderholm SC. Proposed international conventions for particle size-selective sampling. Ann Occup Hyg. 1989;33:301-20. (Pubitemid 19258363)
26. Kwok PCL, Chan HK. Electrostatics of pharmaceutical inhalation aerosols. J Pharma Pharmacol. 2009;61:1587-99.
27. Melandri C, Tarroni G, Prodi V, DeZaiacomo T, Formignani M, Lomardi CC. Deposition of charged particles in the human airway. J Aerosol Sci. 1983;14:657-69. (Pubitemid 14192210)
28. Yu CP. Precipitation of unipolarly charged particles in cylindrical and spherical vessels. J Aerosol Sci. 1977;8:237-42.
29. Yu CP, Chandra K. Depoition of charged particles from laminar flows in rectangular and cylindrical channels by image force. J Aerosol Sci. 1978;9:175-80. (Pubitemid 8609481)
30. Cohen BS, Qiong JQ, Fang CP, Li W. Deposition of charged particles on lung airways. Health Phys. 1998;74:554-60. (Pubitemid 28191446)
31. Hickey AJ, Martonen TB, Yang Y. Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols. Pharmceutica Acta Helvetiae. 1996;71:185-90. (Pubitemid 26290616)
32. Newman SP. How well do in vitro particle size measurements predict drug delivery in vivo. J Aerosol Med. 1998;11:S97-S104. (Pubitemid 28286040)
33. Marple VA, Olson BA, Miller NC. The role of inertial particle collectors in evaluating pharmaceutical aerosol delivery systems. J Aerosol Med. 1998;11:S139-53. (Pubitemid 28286046)
34. Agnew JE. Characterizing lung aerosol penetration. J Aerosol Med. 1991;4:237-49.
35. Clark AR. In vitro assessment of spacers and reservoir devices. In: Dalby R, Evans R, editors. Respiratory drug delivery II. Boca Raton: CRC Press; 1990. p. 27-31.
36. Newman SP, Pitcairn G, Hooper G, Knoch M. Efficient drug delivery to the lungs from a continuously operated open-vent nebulizer and low pressure compressor system. Eur Respir J. 1994;7:1177-81. (Pubitemid 24187340)
37. Barry PW, O'Callaghan C. In vitro analysis of the output of salbutamol from different nebulizers. Eur Respir J. 1999;1130:1164-9. (Pubitemid 29288946)
38. Leach CL, Davidson PJ, Bouhuys A. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12:1346-53. (Pubitemid 29011427)
39. Newman SP, Moren F, Trofast E, Talaee N, Clarke SW. Deposition and clinical efficiency of terbutaline sulphate from turbuhaler, a new multi-dose powder inhaler. Eur Respir J. 1989;2:247-52. (Pubitemid 19107106)
40. Newman SP, Clarke AR, Talaee N, Clarke SW. Pressurized aerosol deposition in the human lung with and without an "open" spacer device. Thorax. 1989;44:706-10. (Pubitemid 19243266)
41. Newman SP, Clarke AR, Talaee N, Clarke SW. Lung deposition of 5 mg Intal from a pressurized metered dose inhaler assessed by radiotracer technique. Int J Pharm. 1991;74:203-8.
42. Richards J, Hirst P, Pitcairn G, Mahashbde S, Abramowitz W, Nolting A, et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med. 2001;14:197-208. (Pubitemid 32744351)
43. Hirst PH, Pitcairn G, Weers JG, Tarara TE, Clark AR, Dellamary LA, et al. In vivo lung deposition of hollow porous particles from a pressurizedmetered dose inhaler. Pharmaceut Res. 2002;19:258-63.
44. Cheng YS, Fu C, Yazzie D, Zhou Y. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. J Aerosol Med. 2001;14:255-66. (Pubitemid 32744357)
45. Zhang Y, Gilbertson K, Finlay WH. In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar® and Turbuhaler® inhalers. J Aerosol Med. 2007;20:227-35. (Pubitemid 47463180)
46. Borgstrom L, Bondesson E, Moren F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7:73.
47. Newman SP, Pitcairn G, Adkin DA, Vidgren MT, Silvasti M. Comparison of beclomethasone dipropionate delivery by Easyhaler dry powder inhaler and PMDI plus large volume spacer. J Aerosol Med. 2001;14:217-25. (Pubitemid 32744353)
48. Pitcairn GR, Lunghetti G, Ventura P, Newman S. A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler at two inhaled flow rates. Int J Pharma. 1994;102:11-8. (Pubitemid 24042973)
49. Pitcairn GR, Lankinen T, Valkila E, Newman SP. Lung deposition of salbutamol inhaled from the Leiras metered dose powder inhaler. J Aerosol Med. 1995;8:307-11.
50. Cheng KH, Cheng YS, Yeh HC, Swift DL. Measurements of airway dimensions and calculation of mass transfer characteristics of the human oral passage. J Biomed Eng. 1997;119:475-82.
51. Kleinstreuer C, Zhang ZQ. Laminar-to-turbulent fluid-particle flows in a human airway model. Int J Multi Flow. 2003;29:271-89. (Pubitemid 36230269)
52. Zhang Z, Kleinstreuer C, Kim CS, Cheng YS. Vaporizing microdroplet inhalation, transport, and deposition in a human upper airway model. Aerosol Sci Technol. 2004;38:36-49. (Pubitemid 38076351)
53. Fadl A, Wang J, Zhang Z, Cheng YS. Effects of MDI spray angle on aerosol penetration efficiency through an oral airway cast. J Aerosol Sci. 2007;38:865-84.
54. Xi J, Longest PW. Transport and deposition of micro-aerosols in realistic and simplified models of the oral airway. Ann Bio Eng. 2007;35:560-81. (Pubitemid 46448162)
55. Stapleton KW, Guentsch E, Hoskinson MK, Finlay WH. On the suitability of k-ε turbulence modeling for aerosol deposition in the mouth and throat: a comparison with experiment. J Aerosol Sci. 2000;31:739-49. (Pubitemid 30173204)
56. Matida EA, DeHaan WH, Finlay WH, Lange CF. Simulation of particle deposition in an idealized mouth with different small diameter inlets. Aerosol Sci Technol. 2003;37:924-32. (Pubitemid 37267772)
57. Gric B, Finlay WH, Burnell PKP, Heenan AF. In vitro intersubject and intrasubject deposition measurements in realistic mouth-throat geometries. J Aerosol Med. 2004;35:1025-40. (Pubitemid 38993745)
58. Zhou Y, Sun JJ, Cheng YS. Comparison of deposition in the USP and physical mouth-throat models with solid and liquid particles. J Aerosol Med Pulmon Drug Deliv. 2011;24:277-84.
59. Hochrainer D, Holz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat soft mist inhaler and pressurized metered dose inhalers. J Aerosol Sci. 2005;18:273-82. (Pubitemid 41395729)
60. Dunbar CA, Watkins AP, Miller JF. An experimental investigation of the spray issued from a pMDI using laser diagnostic techniques. J Aerosol Med. 1997;10:351-68. (Pubitemid 28006475)
61. Shi HW, Kleinstreuer C. Simulation and analysis of high-speed droplet spray dynamics. J Fluid Eng. 2007;129:621-33. (Pubitemid 46969944)
62. Newman SP, Moren F, Clarke SW. Deposition pattern of nasal sprays in man. Rhinol. 1987;26:111-20.
63. Thorsson L, Newman SP, Weisz A, Trofast E, Moren F. Nasal distribution of budesonide inhaled via a powder inhaler. Rhinol. 1993;31:7-10. (Pubitemid 23158585)
64. Cheng YS, Holmes TD, Gao J, Guilmette RA, Li S, Surakitbanharn Y, et al. Characterization of nasal spray pumps and deposition pattern in a replica of the human nasal airway. J Aerosol Med. 2001;14:267-70.
65. Foo MY, Cheng YS, Su WC, Donovan MD. The influence of spray properties on intranasal deposition. J Aerosol Med. 2007;20:495-508.
66. Suman JD, Laube BL, Lin C, Brouet G, Dalby R. Validity of in vitro tests on aqueous spray pumps as surrogates for nasal deposition. Pharmaceut Res. 2002;19:1-6. (Pubitemid 34075099)
67. Al-Ghananeem AM, Sandefer EP, Doll WJ, Page RC, Chang Y, Digenis GA. Gamma scintigraphy for testing bioequivalence: a case study on two cromolyn sodium nasal spray preparations. Int Pharm. 2008;357:70-6.